Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/AKR1C2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AKR1C2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AKR1C2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AKR1C2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AKR1C2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190165711 | Oral cavity | LP | glycosyl compound metabolic process | 43/4623 | 88/18723 | 7.80e-07 | 2.05e-05 | 43 |
GO:1901654110 | Oral cavity | LP | response to ketone | 78/4623 | 194/18723 | 1.24e-06 | 3.03e-05 | 78 |
GO:190166111 | Oral cavity | LP | quinone metabolic process | 24/4623 | 40/18723 | 2.17e-06 | 4.85e-05 | 24 |
GO:003063812 | Oral cavity | LP | polyketide metabolic process | 8/4623 | 10/18723 | 3.78e-04 | 3.67e-03 | 8 |
GO:003064711 | Oral cavity | LP | aminoglycoside antibiotic metabolic process | 8/4623 | 10/18723 | 3.78e-04 | 3.67e-03 | 8 |
GO:004459812 | Oral cavity | LP | doxorubicin metabolic process | 8/4623 | 10/18723 | 3.78e-04 | 3.67e-03 | 8 |
GO:000606613 | Oral cavity | LP | alcohol metabolic process | 111/4623 | 353/18723 | 2.24e-03 | 1.62e-02 | 111 |
GO:00161372 | Oral cavity | LP | glycoside metabolic process | 12/4623 | 22/18723 | 2.55e-03 | 1.80e-02 | 12 |
GO:004218012 | Oral cavity | LP | cellular ketone metabolic process | 70/4623 | 211/18723 | 3.29e-03 | 2.21e-02 | 70 |
GO:007139812 | Oral cavity | LP | cellular response to fatty acid | 17/4623 | 38/18723 | 5.48e-03 | 3.32e-02 | 17 |
GO:0097305110 | Oral cavity | LP | response to alcohol | 80/4623 | 253/18723 | 7.24e-03 | 4.05e-02 | 80 |
GO:007054212 | Oral cavity | LP | response to fatty acid | 25/4623 | 64/18723 | 7.63e-03 | 4.20e-02 | 25 |
GO:1901654112 | Skin | cSCC | response to ketone | 79/4864 | 194/18723 | 4.82e-06 | 7.06e-05 | 79 |
GO:00306387 | Skin | cSCC | polyketide metabolic process | 8/4864 | 10/18723 | 5.51e-04 | 4.04e-03 | 8 |
GO:00306477 | Skin | cSCC | aminoglycoside antibiotic metabolic process | 8/4864 | 10/18723 | 5.51e-04 | 4.04e-03 | 8 |
GO:00445987 | Skin | cSCC | doxorubicin metabolic process | 8/4864 | 10/18723 | 5.51e-04 | 4.04e-03 | 8 |
GO:19016575 | Skin | cSCC | glycosyl compound metabolic process | 37/4864 | 88/18723 | 7.39e-04 | 5.15e-03 | 37 |
GO:190165514 | Skin | cSCC | cellular response to ketone | 38/4864 | 96/18723 | 2.38e-03 | 1.38e-02 | 38 |
GO:19016615 | Skin | cSCC | quinone metabolic process | 18/4864 | 40/18723 | 7.10e-03 | 3.40e-02 | 18 |
GO:19026443 | Skin | cSCC | tertiary alcohol metabolic process | 11/4864 | 21/18723 | 8.71e-03 | 4.01e-02 | 11 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520839 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa05208115 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0520830 | Oral cavity | OSCC | Chemical carcinogenesis - reactive oxygen species | 150/3704 | 223/8465 | 6.45e-13 | 1.20e-11 | 6.11e-12 | 150 |
hsa05208114 | Oral cavity | OSCC | Chemical carcinogenesis - reactive oxygen species | 150/3704 | 223/8465 | 6.45e-13 | 1.20e-11 | 6.11e-12 | 150 |
hsa05208210 | Oral cavity | LP | Chemical carcinogenesis - reactive oxygen species | 119/2418 | 223/8465 | 3.00e-15 | 8.32e-14 | 5.37e-14 | 119 |
hsa0520838 | Oral cavity | LP | Chemical carcinogenesis - reactive oxygen species | 119/2418 | 223/8465 | 3.00e-15 | 8.32e-14 | 5.37e-14 | 119 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKR1C2 | SNV | Missense_Mutation | rs782255440 | c.139C>T | p.His47Tyr | p.H47Y | P52895 | protein_coding | deleterious(0.02) | benign(0.001) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
AKR1C2 | SNV | Missense_Mutation | | c.580C>G | p.His194Asp | p.H194D | P52895 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
AKR1C2 | SNV | Missense_Mutation | | c.362N>T | p.Ser121Phe | p.S121F | P52895 | protein_coding | tolerated(0.06) | possibly_damaging(0.597) | TCGA-D8-A1XA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKR1C2 | SNV | Missense_Mutation | | c.504N>G | p.Phe168Leu | p.F168L | P52895 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
AKR1C2 | SNV | Missense_Mutation | rs781814762 | c.197N>A | p.Arg66Gln | p.R66Q | P52895 | protein_coding | tolerated(0.15) | benign(0.055) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AKR1C2 | SNV | Missense_Mutation | rs782385243 | c.749N>A | p.Arg250Gln | p.R250Q | P52895 | protein_coding | tolerated(0.23) | benign(0.044) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKR1C2 | SNV | Missense_Mutation | novel | c.55C>A | p.Leu19Met | p.L19M | P52895 | protein_coding | deleterious(0.02) | probably_damaging(0.921) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
AKR1C2 | SNV | Missense_Mutation | | c.394N>T | p.Asp132Tyr | p.D132Y | P52895 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
AKR1C2 | SNV | Missense_Mutation | novel | c.627N>C | p.Lys209Asn | p.K209N | P52895 | protein_coding | tolerated(0.14) | benign(0.062) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
AKR1C2 | SNV | Missense_Mutation | novel | c.325N>A | p.Asp109Asn | p.D109N | P52895 | protein_coding | tolerated(0.07) | benign(0.358) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |